XML 44 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9

Collaborative Research and Development Agreements (Tables)

12 Months Ended

Dec. 31, 2014

National Institutes Of Health

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues recognized under the various arrangements with the NIH and NIAID, included as grant revenue in our consolidated statements of operations (in thousands):

		Year ended December 31,
		2014				2013				2012
NIAID contracts		$	2,095			$	4,103			$	3,571
All other NIH contracts			593				1,035				368
Total grant revenue		$	2,688			$	5,138			$	3,939

Agreement With Gsk

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues recognized under our agreement with GSK, included as collaboration revenue in our consolidated statements of operations (in thousands):

		Year ended December 31,
		2014				2013				2012
Initial payment		$	2,524			$	1,702			$	1,428
Total		$	2,524			$	1,702			$	1,428

Astra Zeneca

Summary of Revenue Recognized under Various Agreements

The following table summarizes the revenues earned under our agreement with AstraZeneca, included as collaboration revenue in our consolidated statements of operations (in thousands):

		Year ended December 31,
		2014				2013				2012
Initial payment		$	681			$	720			$	720
Subsequent payment			2,554				-				-
Performance of research activities			2,174				2,507				2,462
Total		$	5,409			$	3,227			$	3,182

X

- Definition

Tabular disclosure of the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement. This item includes certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 25

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=19771336&loc=SL6750900-111635



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 25

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=19771336&loc=d3e50766-111635

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	dei_LegalEntityAxis=dvax_AgreementWithGskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=dvax_AstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=dvax_NationalInstitutesOfHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: